Protagonist Therapeutics (PTGX) Change in Accured Expenses (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Change in Accured Expenses data on file, last reported at -$10.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 8.67% year-over-year to -$10.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.6 million (up 220.24% YoY), and the FY2025 full-year result was $4.6 million, up 6.69% from the prior year.
• Change in Accured Expenses retreated to -$10.8 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q3 2025 to a low of -$11.8 million in Q1 2025.
• A 5-year average of -$1.2 million and a median of -$1.4 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses sank 659.29% in 2022 and soared 353.05% in 2025, its largest moves.
• Tracing PTGX's Change in Accured Expenses over 5 years: stood at -$4.6 million in 2022, then dropped by 16.35% to -$5.3 million in 2023, then soared by 160.47% to $3.2 million in 2024, then surged by 67.57% to $5.4 million in 2025, then plunged by 299.52% to -$10.8 million in 2026.
• Business Quant data shows PTGX's Change in Accured Expenses at -$10.8 million in Q1 2026, $5.4 million in Q4 2025, and $7.5 million in Q3 2025.